{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:05:32Z","timestamp":1794013532369,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004769","name":"Universit\u00e0 degli Studi di Pavia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Factors driving the persistence of advanced therapies\u2014defined as the duration from therapy initiation to discontinuation\u2014in inflammatory bowel disease (IBD) remain unclear. This study aimed to evaluate the persistence of biologics and oral small molecules in a real-word IBD cohort and to identify influencing factors. Data from IBD patients starting advanced therapy at a tertiary referral centre after 2010 were retrospectively collected, including persistence and discontinuation reasons. Differences in persistence probability among therapies were analysed, and factors influencing persistence versus discontinuation due to failure were assessed by univariate and multivariate analyses. Among 274 included patients [median age 42.5 years; F\/M 119\/155; 146 with Crohn\u2019s disease (CD) and 128 with ulcerative colitis; median follow-up 38 months (IQR 14\u201375)], 141 (51.5%) remained persistent with first-line therapy, while 70 (26%) discontinued due to failure. No significant difference in persistence was observed among drugs (<jats:italic>p<\/jats:italic>\u2009= 0.11). Univariate analysis identified CD phenotype (<jats:italic>p<\/jats:italic>\u2009&lt; 0.01), disease duration prior to therapy (<jats:italic>p<\/jats:italic>\u2009= 0.01), concomitant mesalamine or steroids (<jats:italic>p<\/jats:italic>\u2009&lt; 0.01), and therapy optimisation (<jats:italic>p<\/jats:italic>\u2009&lt; 0.01) as factors influencing persistence. Multivariate analysis confirmed CD phenotype as associated with higher persistence, while therapy optimisation was linked to increased discontinuation risk. CD was associated with better drug persistence, while therapy optimisation correlated with a higher discontinuation rate. Targeting deep healing and enhancing timely, precise optimisation strategies is essential for improving treatment outcomes.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1007\/s11739-025-03943-1","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T11:21:54Z","timestamp":1745580114000},"page":"1361-1370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Factors driving persistence to first-line advanced therapies in inflammatory bowel disease: a real-world study from a tertiary referral centre"],"prefix":"10.1007","volume":"20","author":[{"given":"Marco Vincenzo","family":"Lenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Santacroce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Lepore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mord\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lo Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Aronico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Mengoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Delliponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Frondana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iara Moreira","family":"Frondana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0302-8645","authenticated-orcid":false,"given":"Antonio","family":"Di Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"3943_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11082249","author":"E Bretto","year":"2023","unstructured":"Bretto E, Ribaldone DG, Caviglia GP, Saracco GM, Bugianesi E, Frara S (2023) Inflammatory bowel disease: emerging therapies and future treatment strategies. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11082249","journal-title":"Biomedicines"},{"issue":"7","key":"3943_CR2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41573-024-00953-0","volume":"23","author":"S Honap","year":"2024","unstructured":"Honap S, Jairath V, Danese S, Peyrin-Biroulet L (2024) Navigating the complexities of drug development for inflammatory bowel disease. Nat Rev Drug Discov 23(7):546\u2013562. https:\/\/doi.org\/10.1038\/s41573-024-00953-0","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"3943_CR3","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","volume":"162","author":"T Raine","year":"2022","unstructured":"Raine T, Danese S (2022) Breaking through the therapeutic ceiling: what will it take? Gastroenterology 162(5):1507\u20131511. https:\/\/doi.org\/10.1053\/j.gastro.2021.09.078","journal-title":"Gastroenterology"},{"issue":"7","key":"3943_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S2468-1253(21)00065-0","volume":"6","author":"D Alsoud","year":"2021","unstructured":"Alsoud D, Verstockt B, Fiocchi C, Vermeire S (2021) Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol 6(7):589\u2013595. https:\/\/doi.org\/10.1016\/S2468-1253(21)00065-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3943_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1031998","author":"MV Lenti","year":"2023","unstructured":"Lenti MV, Scribano ML, Biancone L et al (2023) Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease. Front Med (Lausanne). https:\/\/doi.org\/10.3389\/fmed.2023.1031998","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"3943_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence: terminology and definitions. Value in Health 11(1):44\u201347. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00213.x","journal-title":"Value in Health"},{"issue":"5","key":"3943_CR7","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s10620-019-05867-1","volume":"65","author":"YS Jung","year":"2020","unstructured":"Jung YS, Han M, Park S, Cheon JH (2020) Biologic use patterns and predictors for non-persistence and switching of biologics in patients with inflammatory bowel disease: a nationwide population-based study. Dig Dis Sci 65(5):1436\u20131444. https:\/\/doi.org\/10.1007\/s10620-019-05867-1","journal-title":"Dig Dis Sci"},{"issue":"11","key":"3943_CR8","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/apt.18006","volume":"59","author":"TH Yiu","year":"2024","unstructured":"Yiu TH, Ko Y, Pudipeddi A, Natale P, Leong RW (2024) Meta-analysis: persistence of advanced therapies in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 59(11):1312\u20131334. https:\/\/doi.org\/10.1111\/apt.18006","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3943_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","volume":"13","author":"C Maaser","year":"2019","unstructured":"Maaser C, Sturm A, Vavricka SR et al (2019) ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 13(2):144-164K. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy113","journal-title":"J Crohns Colitis"},{"issue":"1","key":"3943_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J et al (2022) ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis 16(1):2\u201317. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab178","journal-title":"J Crohns Colitis"},{"issue":"1","key":"3943_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G et al (2020) ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis 14(1):4\u201322. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz180","journal-title":"J Crohns Colitis"},{"issue":"6","key":"3943_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM et al (2011) Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676\u2013682. https:\/\/doi.org\/10.1093\/aje\/kwq433","journal-title":"Am J Epidemiol"},{"key":"3943_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231159452","author":"B Bressler","year":"2023","unstructured":"Bressler B (2023) Is there an optimal sequence of biologic therapies for inflammatory bowel disease? Therap Adv Gastroenterol. https:\/\/doi.org\/10.1177\/17562848231159452","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"3943_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/apt.14852","volume":"48","author":"S Singh","year":"2018","unstructured":"Singh S, Fumery M, Sandborn WJ, Murad MH (2018) Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn\u2019s disease. Aliment Pharmacol Ther 48(4):394\u2013409. https:\/\/doi.org\/10.1111\/apt.14852","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"3943_CR15","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","volume":"18","author":"S Singh","year":"2020","unstructured":"Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ (2020) First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol 18(10):2179-2191.e6. https:\/\/doi.org\/10.1016\/j.cgh.2020.01.008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"3943_CR16","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.dld.2021.11.014","volume":"54","author":"M Attauabi","year":"2022","unstructured":"Attauabi M, Madsen GR, Bendtsen F, Seidelin JB, Burisch J (2022) Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn\u2019s disease\u2014a systematic review with meta-analysis. Dig Liver Dis 54(9):1168\u20131178. https:\/\/doi.org\/10.1016\/j.dld.2021.11.014","journal-title":"Dig Liver Dis"},{"issue":"4","key":"3943_CR17","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","volume":"21","author":"V Solitano","year":"2023","unstructured":"Solitano V, Facciorusso A, Jess T et al (2023) Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 21(4):907-921.e2. https:\/\/doi.org\/10.1016\/j.cgh.2022.07.032","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"3943_CR18","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV et al (2019) Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 381(13):1215\u20131226. https:\/\/doi.org\/10.1056\/NEJMoa1905725","journal-title":"N Engl J Med"},{"issue":"10342","key":"3943_CR19","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","volume":"399","author":"BE Sands","year":"2022","unstructured":"Sands BE, Irving PM, Hoops T et al (2022) Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. The Lancet 399(10342):2200\u20132211. https:\/\/doi.org\/10.1016\/S0140-6736(22)00688-2","journal-title":"The Lancet"},{"issue":"3","key":"3943_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa2314585","volume":"391","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Chapman JC, Colombel JF et al (2024) Risankizumab versus ustekinumab for moderate-to-severe Crohn\u2019s disease. N Engl J Med 391(3):213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa2314585","journal-title":"N Engl J Med"},{"issue":"6","key":"3943_CR21","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","volume":"18","author":"C Kapizioni","year":"2024","unstructured":"Kapizioni C, Desoki R, Lam D et al (2024) Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource. J Crohns Colitis 18(6):790\u2013800. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad203","journal-title":"J Crohns Colitis"},{"issue":"10","key":"3943_CR22","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1016\/j.cgh.2023.01.038","volume":"21","author":"S Ibing","year":"2023","unstructured":"Ibing S, Cho JH, B\u00f6ttinger EP, Ungaro RC (2023) Second-line biologic therapy following tumor necrosis factor antagonist failure: a real-world propensity score-weighted analysis. Clin Gastroenterol Hepatol 21(10):2629\u20132638. https:\/\/doi.org\/10.1016\/j.cgh.2023.01.038","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"3943_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","volume":"9","author":"NM Noor","year":"2024","unstructured":"Noor NM, Lee JC, Bond S et al (2024) A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol 9(5):415\u2013427. https:\/\/doi.org\/10.1016\/S2468-1253(24)00034-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3943_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2024-102805","author":"S Hancox","year":"2024","unstructured":"Hancox S, Morda F, Black CJ, Selinger CP (2024) Comparison of subcutaneous and intravenous infliximab in patients with inflammatory bowel disease showed no differences in immunogenicity or treatment persistence at 1 year. Frontline Gastroenterol. https:\/\/doi.org\/10.1136\/flgastro-2024-102805","journal-title":"Frontline Gastroenterol"},{"key":"3943_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae159","author":"BE Sands","year":"2024","unstructured":"Sands BE, Danese S, Chapman JC et al (2024) Mucosal and transmural healing and long-term outcomes in Crohn\u2019s disease. Inflamm Bowel Dis. https:\/\/doi.org\/10.1093\/ibd\/izae159","journal-title":"Inflamm Bowel Dis"},{"key":"3943_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2017.1284587","author":"MV Lenti","year":"2017","unstructured":"Lenti MV, Selinger CP (2017) Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions. Expert Rev Gastroenterol Hepatol. https:\/\/doi.org\/10.1080\/17474124.2017.1284587","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"3943_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae140","author":"R Porth","year":"2024","unstructured":"Porth R, Deyhim T, Zullow S et al (2024) Proactive therapeutic drug monitoring is associated with increased drug persistence in patients with inflammatory bowel disease treated with intravenous vedolizumab. Inflamm Bowel Dis. https:\/\/doi.org\/10.1093\/ibd\/izae140","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"3943_CR28","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.3390\/biomedicines11061757","volume":"11","author":"KS Garcia","year":"2023","unstructured":"Garcia KS, de Azevedo MFC, de Carlos AS et al (2023) Efficacy of early optimization of infliximab guided by therapeutic drug monitoring during induction\u2014a prospective trial. Biomedicines 11(6):1757. https:\/\/doi.org\/10.3390\/biomedicines11061757","journal-title":"Biomedicines"},{"issue":"5","key":"3943_CR29","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.gastro.2024.01.041","volume":"166","author":"R Lujan","year":"2024","unstructured":"Lujan R, Buchuk R, Focht G et al (2024) Early initiation of biologics and disease outcomes in adults and children with inflammatory bowel diseases: results from the epidemiology group of the nationwide israeli inflammatory bowel disease research nucleus cohort. Gastroenterology 166(5):815-825.e22. https:\/\/doi.org\/10.1053\/j.gastro.2024.01.041","journal-title":"Gastroenterology"},{"issue":"11","key":"3943_CR30","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1016\/j.cgh.2022.02.021","volume":"20","author":"LE Targownik","year":"2022","unstructured":"Targownik LE, Bernstein CN, Benchimol EI et al (2022) Earlier anti-TNF initiation leads to long-term lower health care utilization in Crohn\u2019s disease but not in ulcerative colitis. Clin Gastroenterol Hepatol 20(11):2607-2618.e14. https:\/\/doi.org\/10.1016\/j.cgh.2022.02.021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"3943_CR31","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.cgh.2019.08.012","volume":"18","author":"RC Ungaro","year":"2020","unstructured":"Ungaro RC, Limketkai BN, Jensen CB et al (2020) Stopping mesalamine therapy in patients with Crohn\u2019s disease starting biologic therapy does not increase risk of adverse outcomes. Clin Gastroenterol Hepatol 18(5):1152-1160.e1. https:\/\/doi.org\/10.1016\/j.cgh.2019.08.012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3943_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae240","author":"BC da Silva","year":"2024","unstructured":"da Silva BC, Papasotiriou S, Hanauer SB (2024) Corticosteroid use in randomized clinical trials of biologics and small molecules in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. https:\/\/doi.org\/10.1093\/ibd\/izae240","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"3943_CR33","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/s41590-024-01994-8","volume":"25","author":"T Thomas","year":"2024","unstructured":"Thomas T, Friedrich M, Rich-Griffin C et al (2024) A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease. Nat Immunol 25(11):2152\u20132165. https:\/\/doi.org\/10.1038\/s41590-024-01994-8","journal-title":"Nat Immunol"},{"key":"3943_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12663","author":"M Iacucci","year":"2024","unstructured":"Iacucci M, Santacroce G (2024) Multi-OMICs orchestration enabled by artificial intelligence in inflammatory bowel disease: an exciting future. United Eur Gastroenterol J. https:\/\/doi.org\/10.1002\/ueg2.12663","journal-title":"United Eur Gastroenterol J"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-025-03943-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-025-03943-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-025-03943-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T08:35:23Z","timestamp":1754555723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-025-03943-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3943"],"URL":"https:\/\/doi.org\/10.1007\/s11739-025-03943-1","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval of the research protocol by Territorial Ethics Committee Lombardy 6 (CET 6 Lombardy); Protocol No. 17919, 2024, dated March 19, 2024.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All procedures performed in the studies involving human paraticiants were in accordance with the ethical standards of the instititional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement"}},{"value":"All participants provided informed consent prior to their partecipation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}